Micro Therapeutics Inc.: The San Clemente developer...
- Share via
Micro Therapeutics Inc.: The San Clemente developer of devices for the diagnosis and treatment of vascular diseases incurred a net loss for the first quarter of $1.8 million, or 33 cents a share, compared with a net loss of $1.2 million, or 37 cents a share, for the first quarter last year. Sales more than doubled to $510,039 from $232,913. The company completed its initial public offering on Feb. 18.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
